[1] Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study[J]. Lancet Gastroenterol Hepatol, 2017,2(3):161-176.
[2] Vos T, Barber RM, Bell B, et al.Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet,2015,386(9995):743-800.
[3] Song Y, Bian Y, Petzold M, et al.Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010[J]. PLoS One,2014 ,9(4):e94528.
[4] Xia GL, Liu CB, Cao HL, et al.Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China[J]. International Hepatology Communications,1996, 5(1):62-73.
[5] 陈园生, 李黎, 崔富强, 等.中国丙肝血清流行病学研究[J].中华流行病学杂志,2011,32( 9) : 888-891.
[6] 谢旭,马汉武,路滟,等. 2010年深圳市丙型病毒性肝炎血清流行病学调查[J].中华疾病控制杂志, 2012,16(7):604-607.
[7] WHO. Four ways to reduce hepatitis infections in people who inject drugs[J].Cent Eur J Public Health,2012,20( 3) : 207.
[8] Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016[J/OL]. [2018-11-06]. https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30297.
[9] Nelson PK, Mathers BM, Cowie B, et al.Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews[J]. Lancet , 2011,378(9791):571-583.
[10] Zhang T, Liu Y, Zhang Y, et al.Seroprevalence of human herpesvirus 8 and hepatitis C virus among drug users in Shanghai, China[J].Viruses, 2014, 6(6):2519-2530.
[11] Huik K, Avi R, Carrillo A, et al.CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug users[J]. PLoS One,2013,8(7):e70561.
[12] 陶晓燕,冯铁建,石向东,等. 深圳市吸毒人群AIDS流行状况及相关危险因素分析[J]. 中国艾滋病性病,2004,10(5):341-342. |
